Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00655291 · ClinicalTrials.gov registry record · Phase 3

Efficacy of XP20B Following Bunionectomy Surgery

A Phase 3 study of Acute Pain, sponsored by Xanodyne Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
190
Enrollment target
6
Study locations

NCT00655291 is a Phase 3 study of Acute Pain that has completed, run by Xanodyne Pharmaceuticals. The registered enrollment target is 190 participants, below the 264-participant average among 50 other Acute Pain trials with a reported enrollment target (28% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00655291, a Phase 3 study of Acute Pain, has completed, sponsored by Xanodyne Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
190 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to determine if XP20B is an effective treatment for the relief of pain following bunionectomy surgery.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG XP20B

Study Locations (6)

Texas

  • Investigative Site - Austin
  • Investigative Site - Houston
  • Investigative Site - San Marcos

California

  • Investigatve Site - Anaheim

Maryland

  • Investigative Site - Owings Mills

Utah

  • Investigative Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2008-04
Est. Completion 2008-08
Phase Phase 3

Sponsor

Xanodyne Pharmaceuticals

4 total trials

What the Registry Record Tells You About NCT00655291

The ClinicalTrials.gov registry entry for NCT00655291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 50 other Acute Pain trials with a reported enrollment target (28% lower). The listed sponsor is Xanodyne Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00655291 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00655291 about?

NCT00655291 is a clinical study titled "Efficacy of XP20B Following Bunionectomy Surgery". The purpose of this study is to determine if XP20B is an effective treatment for the relief of pain following bunionectomy surgery.

What is the current status of trial NCT00655291?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2008-04. Estimated completion is 2008-08.

What conditions does trial NCT00655291 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT00655291?

The interventions under investigation include: Placebo (DRUG), XP20B (DRUG).

Who is sponsoring clinical trial NCT00655291?

This trial is sponsored by Xanodyne Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00655291 being conducted?

This trial has 6 study locations across California, Maryland, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.